$0.41 EPS Expected for Omnicell, Inc. (OMCL) This Quarter
Analysts forecast that Omnicell, Inc. (NASDAQ:OMCL) will post earnings per share (EPS) of $0.41 for the current quarter, Zacks reports. Three analysts have made estimates for Omnicell’s earnings. The lowest EPS estimate is $0.40 and the highest is $0.43. Omnicell posted earnings per share of $0.40 during the same quarter last year, which would indicate a positive year over year growth rate of 2.5%. The company is scheduled to announce its next quarterly earnings report on Thursday, October 26th.
On average, analysts expect that Omnicell will report full-year earnings of $1.29 per share for the current financial year, with EPS estimates ranging from $1.28 to $1.32. For the next financial year, analysts forecast that the business will report earnings of $2.04 per share, with EPS estimates ranging from $2.00 to $2.11. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Omnicell.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.02 EPS for the quarter, hitting analysts’ consensus estimates of $0.02. The company had revenue of $180.90 million during the quarter, compared to analyst estimates of $174.08 million. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.38 earnings per share.
Several analysts recently weighed in on the company. BidaskClub cut Omnicell from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies reissued a “hold” rating and set a $40.00 price target on shares of Omnicell in a report on Sunday, July 30th. Craig Hallum lifted their price target on Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Dougherty & Co lifted their price target on Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Finally, Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $51.57.
Omnicell (OMCL) traded up 0.29% during mid-day trading on Thursday, hitting $52.50. The stock had a trading volume of 336,440 shares. The firm’s market capitalization is $1.97 billion. The stock’s 50 day moving average price is $49.97 and its 200 day moving average price is $44.59. Omnicell has a one year low of $30.35 and a one year high of $52.70.
In other news, Chairman Randall A. Lipps sold 37,500 shares of Omnicell stock in a transaction on Friday, July 28th. The stock was sold at an average price of $46.00, for a total value of $1,725,000.00. Following the transaction, the chairman now owns 196,551 shares in the company, valued at approximately $9,041,346. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Randall A. Lipps sold 40,000 shares of Omnicell stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $49.76, for a total value of $1,990,400.00. Following the completion of the transaction, the chairman now owns 196,551 shares in the company, valued at approximately $9,780,377.76. The disclosure for this sale can be found here. Insiders sold a total of 184,094 shares of company stock valued at $9,094,791 over the last ninety days. Insiders own 3.77% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. bought a new stake in Omnicell during the 1st quarter worth $125,000. Oppenheimer Asset Management Inc. bought a new stake in Omnicell during the 1st quarter worth $170,000. Turner Investments LLC bought a new stake in Omnicell during the 2nd quarter worth $181,000. Riverhead Capital Management LLC grew its position in Omnicell by 76.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock worth $182,000 after acquiring an additional 1,830 shares during the last quarter. Finally, Flinton Capital Management LLC grew its position in Omnicell by 74.6% during the 2nd quarter. Flinton Capital Management LLC now owns 4,216 shares of the company’s stock worth $182,000 after acquiring an additional 1,802 shares during the last quarter. Institutional investors own 96.35% of the company’s stock.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.